Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles

Executive Summary

First four 351(k) BLA approvals highlight emerging FDA positions on issues from naming to the role of biosimilar-specific data, as detailed in Pink Sheet's Drug Review Profile series.


Related Content

Mylan, Amgen Biosimilars Sail Through Advisory Panels, May Diverge From There
US Biosimilars: 40% First-Cycle Approval Rate Leaves Room For Improvement
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
Novel Biologics In US Might Not Start Getting Suffixes Until August
Sandoz Tested Erelzi’s Suffix On Multiple Fronts
How To Name A Biosimilar: Amgen Persisted With Amjevita Suffix Despite FDA Doubts
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
Evolving Biosimilar Pathway Brings Mid-Review Policy Issues
Biosimilar Naming: FDA Asked Celltrion For Two Kinds Of Suffixes
How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts